Company: DMAAR
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001213900-25-026240
Chunk: 90

Company: Drugs Made In America Acquisition Corp.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 1A
Chunk 90
---
 Philanthropy (AHP). Ms. Stockwell is also actively involved in advancing the professional development
of women in the life sciences through her membership in the BioIndustry Association (BIA), where she focuses on scholarship opportunities.
Additionally, she is a member of the National Breast Cancer Coalition, reflecting her commitment to impactful healthcare advocacy.

Glenn Worman has been our Chief Financial
Officer since July 2024. Mr. Worman has been a Partner in the New York office of SeatonHill Partners, LP since November 2022.
He has served as CFO of Orion Innovations Inc. since February 2025. Mr. Worman served as Chief Financial Officer of Insight Acquisition
Corp., a special purpose acquisition company, from April 2024 until the completion of its business combination with Alpha Modus,
Corp. in December 2024. Between 2015 and 2022, Mr. Worman served as the CFO and President of National Holdings Corporation. From
2011 to 2015, he served as the Chief Financial Officer for the Americas for ICAP, plc. Prior to ICAP, plc, Mr. Worman held senior
positions at, among other companies, Deutsche Bank, Morgan Stanley, and Merrill Lynch. Mr. Worman is an accomplished and diverse
financial services executive with a history of providing strong, effective leadership and developing and executing strategy across a spectrum
of businesses. With nearly four decades of experience, he is adept at organizational analysis and implementing change, ensuring proper
controls and sources of liquidity are in place, and advising executive management on business direction. Mr. Worman’s prior
experience in senior finance and chief operating officer positions in corporate finance, fixed income and equity capital markets, wealth
management, investment management, strategic analysis, interdealer brokerage, and compliance underscore his ability to handle industry
segment and public company chief financial officer requirements. Mr. Worman earned a BS degree from Ramapo College of New Jersey
and an MBA from Fairleigh Dickinson University.

Catherine Do has served as a member of
our board of directors since January 2025. Dr. Do was trained as a medical doctor specializing in Public Health and Epidemiology
in France, with a keen interest in molecular epidemiology. Due to the absence of a joint PhD-MD program in France, she paused her residency
to earn a master’s in Biostatistics and Clinical Research and a PhD in Molecular Pharmacology. After spending a